Industry Reports

Sumitomo Dainippon Pharma Co., Ltd. (4506) - Financial and Strategic SWOT Analysis Review

Tuesday, Oct 04, 2016

Sumitomo Dainippon Pharma Co Ltd (Sumitomo Dainippon), a subsidiary of Sumitomo Chemical Co., Ltd, is a pharmaceutical company. It develops manufacturers, purchases, sells, imports and exports pharmaceutical products. The company’s major products include LATUDA, APTIOM, BROVANA, REPLAGAL AIMIX, AMLODIN, TRERIEF, METAGLUCO and MEROPEN. Sumitomo Dainippon focuses on central nervous system (CNS), cardiovascular, diabetes, oncology, respiratory psychiatry and neurology and infectious diseases. The company also offers veterinary products, food additives, food ingredients, diagnostic agents, research materials and other products. The company operates manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in the North America, Europe and Asia Pacific. Sumitomo Dainippon is headquartered in Chuo-ku, Osaka, Japan. This comprehensive SWOT profile of Sumitomo Dainippon Pharma Co Ltd provides you an in-depth strategic analysis of the company’s businesses and operations.

Read More>